scholarly journals An Aggressive Liposarcoma Presenting as a Perforated Colon Mass

Cureus ◽  
2021 ◽  
Author(s):  
Rebecca Innes ◽  
Sylvester Paulasir ◽  
Lesley Combs
Keyword(s):  
Perforated Colon

scholarly journals Retroperitoneal Abscess due to Perforated Colon Cancer. Report of Three Cases.

1992 ◽  
Vol 25 (8) ◽  
pp. 2232-2236
Author(s):  
Hiromi Nakayama ◽  
Koki Tanaka ◽  
Mitsunobu Uto ◽  
Akira Taira
Keyword(s):  
Colon Cancer ◽  
Retroperitoneal Abscess ◽  
Perforated Colon

Dealing with the Perforated Colon

1980 ◽  
pp. 61-62
Author(s):  
A. Ochsner ◽  
H. Trede ◽  
P. Berger ◽  
J. H. Johnston
Keyword(s):  
Perforated Colon

scholarly journals The Assassination of Anton Cermak, Mayor of Chicago: A Review of His Postinjury Medical Care

2020 ◽  
Vol 06 (02) ◽  
pp. e105-e111
Author(s):  
Theodore N. Pappas
Keyword(s):  
Medical Care ◽  
Gunshot Wound ◽  
Clinical Course ◽  
Local Hospital ◽  
Autopsy Findings ◽  
President Elect ◽  
Franklin Delano Roosevelt ◽  
Perforated Colon ◽  
Toxic Colitis

AbstractAnton Cermak was the mayor of Chicago in the 1930s. He was injured by an assassin's bullet intended for the president-elect, Franklin Delano Roosevelt. Cermak was taken to a local hospital, treated nonoperatively for his injuries, and initially improved. Cermak's condition deteriorated on the sixth day postinjury, with symptoms that his doctors described as colitis. He died of sepsis on the 19th day after the shooting, and his autopsy revealed a perforated colon causing peritonitis. This study will review Cermak's clinical course and autopsy findings to determine if he died of his gunshot wound or if he died of complications of toxic colitis.

Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 482-482 ◽  
Author(s):  
Charlotte Emma Louise Klaver ◽  
Daniel D Wisselink ◽  
Cornelis J. A. Punt ◽  
Petur Snaebjornsson ◽  
Johannes Crezee ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Systemic Chemotherapy ◽  
Tumor Resection ◽  
Multicenter Trial ◽  
Peritoneal Metastases ◽  
Long Term Results ◽  
Control Versus ◽  
Drop Outs ◽  
Perforated Colon

482 Background: Patients with T4 or perforated colon cancer are at high risk (~25%) of peritoneal metastases (PM). Sensitivity of imaging modalities for PM is limited and the majority of patients is diagnosed in a palliative setting. This provides a rationale for adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). In this study, the effectiveness of adjuvant HIPEC in reducing the risk of PM was determined. Methods: In this multicenter trial, patients with T4 (either cT4 or pT4, N0-2, M0) or perforated colon cancer, who underwent curative resection were randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy or to adjuvant systemic chemotherapy alone (1:1). Adjuvant HIPEC with oxaliplatin was performed simultaneously (9%) or within five-eight weeks (91%) after the primary tumor resection. Patients without evidence of recurrent disease at 18 months based on CT imaging underwent diagnostic laparoscopy in both arms. The primary endpoint was PM free survival (PMFS) at 18 months using Kaplan Meier analysis. Results: Between April 2015 and January 2017, 204 patients were randomized: 102 in the control arm (0 drop-outs), 102 in the experimental arm (two drop-outs). Surgical exploration at the start of the HIPEC procedure at five-eight weeks postoperatively revealed metastases in 11 patients (PM in 9/11) in the experimental arm, and adjuvant HIPEC was not applied. Adjuvant systemic chemotherapy was administered in 89/100 eligible patients after median 6 weeks (IQR 5-7) in the control arm and in 84/89 after 10 weeks (IQR 9-12) in the experimental arm. PM rate after completion of 18 months follow-up was 22/102 and 18/100, respectively. In the ITT analysis no difference in 18 months PMFS was observed: 77% (control) versus 81% (experimental), HR 0.836 (0.489-1.428)). Also, no differences were observed in 18 months DFS (HR 1.016 (0.646-1.598)) and OS (HR 1.139 (0.532-2.439)). One patient developed encapsulating peritoneal sclerosis after HIPEC. Conclusions: Adjuvant HIPEC with oxaliplatin for patients with T4 or perforated colon cancer does not result in improved 18 months PMFS. Long-term results have to be awaited to assess the role of HIPEC in the adjuvant setting. Clinical trial information: NCT02231086.

A Hemophagocytic Syndrome-Like Condition After Emergency Colectomy for Perforated Colon Cancer: Report of a Case

Surgery Today ◽  
2002 ◽  
Vol 32 (3) ◽  
pp. 278-281 ◽  
Author(s):  
Takayuki Yamada ◽  
Toshiro Ikeya ◽  
Tetsushi Ogawa ◽  
Minoru Nakano ◽  
Hidemi Ogura ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Hemophagocytic Syndrome ◽  
Emergency Colectomy ◽  
Perforated Colon

scholarly journals Neutrophil-to-lymphocyte ratio has limited predictive value for determining outcomes in perforated colon cancer: a propensity score analysis.

2020 ◽  
Author(s):  
Chunyi Wu ◽  
Jy-Ming Chiang ◽  
Jeng-Fu You ◽  
Reiping Tang ◽  
Jinn-Shiun Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Disease Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Disease Free ◽  
Perforated Colon

Abstract Background: The neutrophil-to-lymphocyte ratio is a significant prognostic marker in resectable colorectal cancer; however, there are no equivalent findings for perforated colon cancer. Using our colorectal cancer database, we retrospectively analyzed the data from 1995 to 2015 to determine whether the preoperative neutrophil-to-lymphocyte ratio is associated with survival outcomes in patients with perforated colon cancer.Methods: One-to-one propensity score matching was applied to minimize the difference between the high (>5) and low (≤5) neutrophil-to-lymphocyte ratio groups. Clinicopathological factors, long-term overall survival, and disease-free survival were analyzed and compared between the two groups. The primary outcomes were overall survival and disease-free survival.Results: Before propensity score matching, the high neutrophil-to-lymphocyte ratio group had a significantly higher prevalence of leukocytosis (low vs. high neutrophil-to-lymphocyte ratio groups: 12 [12.9%] vs. 46 [59.7%], p<0.001), lower serum albumin levels (low vs. high neutrophil-to-lymphocyte ratio groups: 30 [32.3%] vs. 42 [54.5%], p=0.003), and a higher emergent operation rate (low vs. high neutrophil-to-lymphocyte ratio groups: 5 [5.4%] vs. 20 [26.0%], p<0.001). After one-to-one propensity score matching, the groups comprised 41 patients each; none of the parameters were significantly different between the two groups. The mean follow-up period was 76.3 months. The 5-year overall survival (p=0.637) and disease-free survival (p=0.827) rates were not significantly different between the high and low neutrophil-to-lymphocyte ratio groups.Conclusions: The neutrophil-to-lymphocyte ratio has limited predictive value for determining outcomes in patients with perforated colon cancer.

Sign in / Sign up

Export Citation Format

Share Document